Telomir Pharmaceuticals Files 8-K Report
Ticker: TELO · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, SEC Filing, Other Events
TL;DR
Telomir Pharma filed an 8-K on Oct 14, 2025. Details TBD.
AI Summary
On October 14, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Telomir Pharmaceuticals has reported a material event to the SEC, which could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without specific details of negative events, making the immediate risk level low based on the provided information.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- October 14, 2025 (date) — Date of earliest event reported
- Miami, Florida (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Telomir Pharmaceuticals?
The provided excerpt of the 8-K filing does not specify the details of the 'Other Events'.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 14, 2025.
What is the principal executive office address for Telomir Pharmaceuticals?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida, 33131.
What is the SEC file number for Telomir Pharmaceuticals?
The SEC file number for Telomir Pharmaceuticals is 001-41952.
What is the standard industrial classification for Telomir Pharmaceuticals?
The Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 16 · Accepted 2025-10-14 07:30:43
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-25-017916.txt ( ) — 203KB
- telo-20251014.xsd (EX-101.SCH) — 3KB
- telo-20251014_lab.xml (EX-101.LAB) — 33KB
- telo-20251014_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Dated: October 14, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer